长期核苷(酸)类抗病毒治疗的乙型肝炎肝硬化患者肝癌发生相关因素研究

doi:10.3969/j.issn.1672-5069.2021.03.030

摘要/Abstract

摘要： 目的探讨长期接受核苷酸抗病毒治疗的乙型肝炎肝硬化患者肝癌发生的相关危险因素。方法 2002年5月～2015年5月接受核苷(酸)类抗病毒治疗的乙型肝炎肝硬化患者417例,平均抗病毒治疗时间为(9.11±2.09)年。记录观察期内原发性肝癌发生情况。采用多元Logistics回归分析导致肝癌发生的危险因素。结果在观察期内,本组417例乙型肝炎肝硬化患者发生原发性肝癌57例(13.7)%;肝癌组在有肝癌家族史、长期饮酒、Child-Pugh C级、未应用一线抗病毒药物、抗病毒治疗后血清HBV DNA水平仍大于20 IU/ml的比率显著高于未发生肝癌组(P<0.05);多因素Logistic分析显示存在肝癌家族史(OR=1.568,95%CI为1.074～2.289,P=0.020)、长期饮酒史(OR=1.791,95%CI为1.227～2.615,P=0.003)、Child-Pugh C级(OR=1.598,95%CI为1.095～2.333,P=0.016)、未应用一线抗病毒药物(OR=1.476,95%CI为0.997～2.168,P=0.047)和抗病毒治疗后血清HBV DNA水平仍未转阴(OR=1.480,95%CI为1.014～2.160,P=0.043)为肝癌发生的独立危险因素。结论本研究经过长期随访观察,发现有肝癌家族史、长期饮酒、Child-Pugh分级C级、未应用一线抗病毒药物治疗和抗病毒治疗后血清HBV DNA仍大于20 IU/ml是导致乙型肝炎肝硬化患者发生肝癌的危险因素,选择一线抗病毒药物治疗、戒酒、改善肝功能状态可能减少肝癌的发生,值得认真对待。

关键词: 原发性肝癌, 肝硬化, 核苷(酸)类, 多因素Logistic分析, 危险因素

Abstract: Objective The aim of this study was to explore the risk factors of liver cancer occurrence in patients with hepatitis B liver cirrhosis receiving long-term nucleot(s)ide antiviral therapy. Methods A total of 417 patients with hepatitis B-induced liver cirrhosis receiving nucleos(t)ide antiviral therapy were followed-up from May 20012 to May 2015, and they underwent imaging check-up regularly for the findings of primary liver cancer (PLC). Multivariate Logistic analysis was applied to find the risk factors of PLC occurrence.Results During the followed-up period, the PLC was found in 57 patients with liver cirrhosis(13.7)%; the univariate Logistic analysis showed that the percentages of family history of liver cancer, long-term alcohol consumption, Child-Pugh class C, non-first line medicine for antiviral therapy and serum HBV DNA greater than 20 IU/ml in patients with PLC were significantly higher than that in cirrhotic patients (P<0.05); the multivariate Logistic analysis demonstrated that family history of liver cancer (OR=1.568, 95%CI:1.074-2.289, P=0.020), long-term alcohol consumption (OR=1.791, 95%CI:1.227-2.615,P=0.003),Child-Pugh class C(OR=1.598,95%CI: 1.095-2.333,P=0.016), non-first line antiviral medicine therapy (OR=1.476,95%CI:0.997-2.168,P=0.047) and still positive serum HBV DNA loads after antiviral therapy (OR=1.480,95%CI:1.014-2.160,P=0.043) were the independent risk factors for liver cancer occurrence.Conclusion We conclude this study with findings of liver cancer family history, long-term drinking, Child-Pugh class C liver functions, not taking first-line antiviral medicines and serum HBV DNA level greater than 20 IU/ml after antiviral therapy being the risk factors of PLC happening, which hints administration of first-line antiviral therapy to obtain sustained virologic response, abstaining drinking and improvement of liver functions appropriately might decrease the liver cancer happening in patients with hepatitis B-induced liver cirrhosis.

Key words: Hepatocellular carcinoma, Liver cirrhosis, Nucleot(s)ide, Multivariate Logistic analysis, Risk factor

谢宁, 黄娟秀, 严柳媚, 廖小莉. 长期核苷(酸)类抗病毒治疗的乙型肝炎肝硬化患者肝癌发生相关因素研究[J]. 实用肝脏病杂志, 2021, 24(3): 423-426.

Xie Ning, Huang Juanxiu, Yan Liumei, et al. Risk factors of liver cancer occurrence in patients with hepatitis B liver cirrhosis receiving long-term nucleot(s)ide antiviral therapy[J]. Journal of Practical Hepatology, 2021, 24(3): 423-426.

参考文献

[1] Sun J, Li Y, Wang Y, et al. Comparison of anti-HBV regimen with or without adefovir on hepatocellular carcinoma development of chronic hepatitis B patients with compensated cirrhosis: a retrospective cohort study. Infect Agent Cancer, 2018, 22(5):13-17.
[2]Lin CC, Bair MJ, Liu CY, et al. High percentage atypical hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs. Medicine (Baltimore), 2019, 98(1):e13818.
[3] 付喜花,张振华,刘婉婷,等.核苷酸类药物治疗乙型肝炎病毒感染导致的慢加急性肝衰竭患者疗效分析.实用肝脏病杂志,2017,20(1):455-459.
[4] 中华医学会肝病学分会.肝硬化腹水及相关并发症的诊疗指南.实用肝脏病杂志,2018,21(1):21-31.
[5] Li Z, Hu Y, Wang H, et al. Predictors for the progression of hepatic cirrhosis to hepatocellular carcinoma under long-term antiviral therapy. Eur J Gastroenterol Hepatol,2019,32(3):1-8.
[6] Chayanupatkul M, Omino R, Mittal S, et al. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J Hepatol,2017,66(2):355-362.
[7] 中国抗癌协会肝癌专业委员会,中华医学会肝病学分会肝癌学组,中国抗癌协会病理专业委员会,等.原发性肝癌规范化病理诊断指南(2015年版).解放军医学杂志,2015,40(11):865-872.
[8] 卢婷,宋玉霞,李成忠.核苷(酸)类药物治疗慢性乙型肝炎和乙型肝炎肝硬化患者血清磷变化及其相关影响因素分析.实用肝脏病杂志,2016,19(2):168-171.
[9] Wei X, Fan C, Zhou Y, et al. TheeEfficacy of add-on telbivudine versus switching to pegylated interferon alfa-2a in chronic hepatitis B patients with poor responses to adefovir. Hepat Mon, 2016, 16(1):e31278.
[10] 许明妍,宋术鹏,兰英华,等.核苷(酸)类似物抗病毒治疗对乙型肝炎病毒相关性肝癌病理分化及预后的影响.中华传染病杂志,2016,34(12):723-726.
[11] Yamada R, Hiramatsu N, Oze T, et al. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection. J Gastroenterol, 2015, 50(7):785-794.
[12] 谷孙泽栋,杨晓飞,张佩欣.恩替卡韦治疗慢性乙型肝炎和乙型肝炎肝硬化患者血清和肝组织可溶性纤维蛋白原样蛋白2水平的变化.实用肝脏病杂志,2019,22(3):405-408.
[13] Cho JY, Paik YH, Sohn W, et al. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Gut, 2014, 63(12):1943-1950.
[14] Watanabe H, Ueno Y. Seroclearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in hepatitis B virus patients during nucleoside/nucleotide analog therapy. Nihon Rinsho., 2015, 73(9):459-465.
[15] Jae A, Jayoun H, Jeong H, et al. Risk factors for developing liver cancer in people with and without liver disease.Plos One,2018,13(10):1-10.
[16] 张原青,彭利军,曹忆嶸,等.慢性乙型肝炎肝硬化患者发生肝细胞癌的危险因素分析.中华肝脏病杂志,2015,23(7):512-516.
[17] Rademacher S, Seehofer D, Eurich D, et al. The 28‐year incidence of de novo malignancies after liver transplantation: A single‐center analysis of risk factors and mortality in 1616 patients.Liver Transpl,2017,23(11):1404-1414.
[18] 史萍,蒋龙凤,李军.慢性乙型肝炎患者核苷(酸)类药物停药后复发的相关因素荟萃分析.中华临床感染病杂志,2015,8(1):58-69.
[19] Fasano M, Montrano L, Ciarallo M, et al. Risk ofhepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogues and long-term virological suppression. J Hepatol,2016,64(2):335-336.
[20] Zhong G C, Liu Y, Chen N, et al. Reproductive factors, menopausal hormone therapies and primary liver cancer risk: a systematic review and dose-response meta-analysis of observational studies.Hum Reprod Update,2016,23(1):126-138.
[21] Liang Y R , Guo Z, Jiang J H, et al. Thymosin α1 therapy subsequent to radical hepatectomy in patients with hepatitis B virus-associated hepatocellular carcinoma: A retrospective controlled study. Oncol Lett,2016,12(5):3513-3518.
[22] Papatheodoridis GV, Idilman R, Dalekos GN, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology, 2017, 66(5):1444-1453.
[23] Mak LY, Lee CH, Cheung KS, et al. Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long-term nucleoside analogue. Liver Int, 2019, 39(7):1217-1225.
[24] 应灵军,陈华忠,张建伟,等.代偿期乙型肝炎肝硬化患者长期抗病毒治疗后临床特点和肝脏组织学改变.中华临床感染病杂志,2016,9(9):13-18.
[25] 卢婷,宋玉霞,李成忠. 核苷(酸)类药物治疗慢性乙型肝炎和乙型肝炎肝硬化患者血清磷变化及其相关影响因素分析.实用肝脏病杂志,2016,19(2):168-171.